Literature DB >> 26086632

State Legislation, Regulations, and Hospital Guidelines for Newborn Screening for Critical Congenital Heart Defects - United States, 2011-2014.

Jill Glidewell, Richard S Olney, Cynthia Hinton, Jim Pawelski, Marci Sontag, Thalia Wood, James E Kucik, Rachel Daskalov, Jeff Hudson.   

Abstract

Critical congenital heart defects (CCHD) occur in approximately two of every 1,000 live births. Newborn screening provides an opportunity for reducing infant morbidity and mortality. In September 2011, the U.S. Department of Health and Human Services (HHS) Secretary endorsed the recommendation that critical congenital heart defects be added to the Recommended Uniform Screening Panel (RUSP) for all newborns. In 2014, CDC collaborated with the American Academy of Pediatrics (AAP) Division of State Government Affairs and the Newborn Screening Technical Assistance and Evaluation Program (NewSTEPs) to assess states' actions for adopting newborn screening for CCHD. Forty-three states have taken action toward newborn screening for CCHD through legislation, regulations, or hospital guidelines. Among those 43, 32 (74%) are collecting or planning to collect CCHD screening data; however, the type of data collected by CCHD newborn screening programs varies by state. State mandates for newborn screening for CCHD will likely increase the number of newborns screened, allowing for the possibility of early identification and prevention of morbidity and mortality. Data collection at the state level is important for surveillance, monitoring of outcomes, and evaluation of state CCHD newborn screening programs.

Entities:  

Mesh:

Year:  2015        PMID: 26086632      PMCID: PMC4584733     

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


Critical congenital heart defects (CCHD) occur in approximately two of every 1,000 live births (1). Newborn screening provides an opportunity for reducing infant morbidity and mortality (2,3). In September 2011, the U.S. Department of Health and Human Services (HHS) Secretary endorsed the recommendation that critical congenital heart defects be added to the Recommended Uniform Screening Panel (RUSP) for all newborns (4). In 2014, CDC collaborated with the American Academy of Pediatrics (AAP) Division of State Government Affairs and the Newborn Screening Technical Assistance and Evaluation Program (NewSTEPs) to assess states’ actions for adopting newborn screening for CCHD. Forty-three states have taken action toward newborn screening for CCHD through legislation, regulations, or hospital guidelines. Among those 43, 32 (74%) are collecting or planning to collect CCHD screening data; however, the type of data collected by CCHD newborn screening programs varies by state. State mandates for newborn screening for CCHD will likely increase the number of newborns screened, allowing for the possibility of early identification and prevention of morbidity and mortality. Data collection at the state level is important for surveillance, monitoring of outcomes, and evaluation of state CCHD newborn screening programs. Congenital heart defects occur in approximately eight of every 1,000 live births, one fourth of which are considered to be CCHD (1). CCHD are defined as those requiring surgery or catheterization before age 1 year. In the absence of early detection, infants with CCHD are at risk for serious complications or death within the first few days or weeks of life (1). Newborn screening for CCHD uses pulse oximetry, a noninvasive technology to measure blood oxygen saturation. Low oxygen saturation indicates hypoxemia, an early clinical sign of CCHD. Additional testing (e.g., repeat screening, echocardiogram) is needed following an abnormal pulse oximetry screen (1) to determine whether CCHD are present (or to determine the cause of the abnormal result). Thus, unlike most newborn screening conditions, screening for CCHD is not based on performing a blood test. In addition, hypoxemia detected by screening could indicate a medical problem, and requires immediate follow-up before discharge from the hospital. When accompanied by early identification and treatment, newborn screening provides an opportunity to reduce infant morbidity and mortality (2,3). The Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children has provided national guidelines and recommendations on newborn screening, known as the RUSP, and this panel is reviewed and endorsed by the HHS Secretary (3). As of March 2015, 32 conditions were included in the RUSP. States use the RUSP as guidance when considering adopting conditions for their own screening panels (3). State decisions might differ depending on method of screening required or the legislative authority of the newborn screening program. When states add conditions to their state-specific screening panels, they do so by state legislation, or rules and regulations (5). In 2010, the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children recommended adding CCHD to the RUSP for all newborns (4). In September 2011, the HHS Secretary endorsed the recommendation. To assess states’ actions for adopting newborn screening for CCHD, CDC collaborated with the AAP Division of State Government Affairs and NewSTEPs. AAP obtained primary information through direct contact and partnership with AAP state chapters. AAP monitored state legislation by use of tracking software; regulations and hospital guidelines were researched on state websites. NewSTEPs is a program of the Association of Public Health Laboratories in collaboration with the Colorado School of Public Health, funded through a cooperative agreement from the Health Resources and Services Administration (6). NewSTEPs maintains a data repository of state newborn screening program metrics and provides education and technical assistance to newborn screening programs. In January 2014, NewSTEPs distributed a survey on CCHD newborn screening adoption and data collection practices to state CCHD newborn screening programs. The survey requested the status of CCHD mandates and requirements for data collection. If data collection was required at the state level, additional information was requested on the type of data collected. All 50 states and the District of Columbia participated. The survey findings indicated that 43 states have legislation, regulations, or hospital guidelines in place supporting CCHD newborn screening; 35 states have legislation, and 13 have regulations related to CCHD screening (Table). Among the 43, three states (Indiana, Maryland, and New Jersey) enacted legislation before the Secretary’s approval of adding CCHD to the RUSP in 2011 (Table). State adoption of CCHD screening peaked in 2013 with 25 states adopting screening (Figure 1).
TABLE

State approvals of legislation, regulation, and hospital guidelines for newborn screening for critical congenital heart defects (CCHD) — United States, 2011–2014

Mechanism of current approval for CCHD screening

StateEnacted dateEffective dateLegislation*Regulation/GuidelinesScreening supported as standard of careData collection system at state levelType of data reported (current or proposed)
AlabamaMay 2013June 2013X§PlannedAll oxygen saturations/times on all failed screens
AlaskaSeptember 2013January 2014 (January 2016 for providers who attend fewer than 20 births a year)X§YesAggregate data
ArizonaApril 2014July 2015X§PlannedAll oxygen saturations/times
ArkansasApril 2013August 2013X§PlannedPass/Fail on all newborns
California*October 2012July 2013X (Screening is required to be offered)YesPass/Fail on all newbornsAll oxygen saturations/times on diagnosed cases
ColoradoXPlannedAll oxygen saturations/times
ConnecticutMay 2012January 2013X§No
DelawareMay 2013May 2013X§YesPass/Fail on all newborns
District of ColumbiaXYesAll oxygen saturations/times (one hospital)
FloridaOctober 2014October 2014X§YesFinal oxygen saturations/times
GeorgiaMay 2014June 2014X§PlannedAll oxygen saturations/times
Hawaii**XPlannedAll oxygen saturations/times
IdahoXNo
IllinoisAugust 2013August 2013X§No
IndianaMay 2011January 2012X§YesAll oxygen saturations/times
Iowa (guidelines)August 2012August 2012X§XNo
Iowa(legislation)April 2013July 2013
KansasXYesAll oxygen saturations/times (four hospitals); Aggregate data (other hospitals)
KentuckyMarch 2013January 2014X§YesAll oxygen saturations/times; Echocardiogram results††
LouisianaJune 2013August 2013X§No
MaineJuly 2013July 2013X§PlannedAll oxygen saturations/times
MarylandMay 2011July 2011X§YesPass/Fail on all newborns; Option to enter all oxygen saturations/times
Massachusetts (guidelines)May 2013May 2013X§XYesAggregate data only
Massachusetts (legislation)March 2014January 2015
MichiganOctober 2013April 2014X§YesAll oxygen saturations/times; Echocardiogram results
MinnesotaMay 2013August 2013X§YesAll oxygen saturations/times
MississippiOctober 2014November 2014X§PlannedAggregate data
MissouriJuly 2013January 2014X§YesAggregate data; Plan to include newborn data with all oxygen saturations/times
MontanaJune 2014July 2014X§PlannedPass/Fail on all newborns
NebraskaJune 2013September 2013X§No
NevadaJune 2013July 2015X§YesAggregate data only (hospitals participating in a pilot program)
New HampshireJune 2012August 2012X§No
New JerseyJune 2011September 2011X§YesAggregate data; Plan to collect all oxygen saturations/times
New MexicoMarch 2014May 2014X§PlannedAll oxygen saturations/times
New YorkJuly 2013January 2014X§No
North CarolinaMay 2013May 2013X§YesAggregate data
North DakotaApril 2013August 2013X§No
OhioJune 2013September 2013X§PlannedAll oxygen saturations/times
OklahomaApril 2013July 2013X§YesPass/Fail on all newborns
OregonJune 2013June 2013X§No
Pennsylvania (regulation)December 2012 (regulation)March 2013 (regulation)X§XYesAggregate data only; Oxygen saturations/time for confirmed cases only
Pennsylvania (legislation)July 2014 (legislation)September 2014 (legislation)
Rhode IslandAugust 2014July 2015X§YesPass/Fail on newborns (some hospitals)
South CarolinaJune 2013June 2013X§No
South DakotaMarch 2013July 2013X§No
Tennessee (legislation)*March 2012 (legislation)January 2013 (legislation)XX§YesPass/Fail and date/time of screen on all newborns
Tennessee (regulation)May 2013 (regulation)May 2013 (regulation)
TexasJune 2013September 2013X§YesAll oxygen saturations on diagnosed cases only
UtahMarch 2013October 2014X§YesPass/Fail on all newbornsPlanned: All oxygen saturations/times
VermontXPlannedAggregate data only on all newborns; Oxygen saturations/times on failed screens
Virginia (executive order)§§June 2012June 2012X§PlannedOxygen saturations/times on failed screens
Virginia (legislation)February 2014July 2014
WashingtonXNo
West VirginiaMarch 2012June 2012X§YesPass/Fail on all newborns
Wisconsin* (legislation)March 2014 (legislation)March 2014 (legislation)X*X§YesPass/Fail on all newborns; All oxygen saturations/times from some hospitals
Wisconsin (regulation)June 2014 (regulation)July 2014 (regulation)
WyomingXPlannedAll oxygen saturations/times

A total of 35 states have enacted legislation related to newborn screening for CCHD; 32 of those state laws require screening. California’s law requires the screen to be offered to parents of newborns before discharge. Tennessee’s law requires the state to develop a program for CCHD screening. Wisconsin’s law allows the state department of health to add conditions or diseases to the state’s newborn screening panel.

A total of 13 states issued regulations or hospital guidelines related to newborn screening; 10 of those states issued regulations requiring screening. Iowa and Massachusetts issued guidelines to hospitals and birthing centers on screening, but the guidelines do not require screening. Pennsylvania issued a regulation requiring reporting of results and diagnoses of screened newborns, but the regulation does not require screening. Tennessee issued a regulation, after enacting legislation, adding CCHD to the state’s newborn screening panel.

Mandates CCHD screening of newborns.

State reports that all hospitals are performing CCHD screening.

Legislation in Hawaii to require screening failed in 2014.

Echocardiogram is the diagnostic test that follows a failed pulse oximetry screen.

Virginia’s former governor issued a directive in 2012 that established a workgroup to develop a plan for implementing screening.

FIGURE 1

Number of states (N = 43) adopting legislation, regulation, or hospital guidelines for universal newborn screening for critical congenital heart defects, by year — United States, 2011–2014

The manner in which these 43 states developed universal screening varied substantially (Figure 2), and for some was a multistage process (Table). For example, California passed legislation requiring that CCHD screening be offered to parents of newborns. In 2013, Pennsylvania issued a regulation requiring reporting of results and diagnoses of screened newborns. However, the regulation did not mandate screening. In 2014, Pennsylvania enacted a law requiring screening. In 2012, Tennessee initially passed legislation that required the state’s genetic advisory committee to develop a program for addition of CCHD to its screening panel. In 2013, Tennessee added CCHD to its panel via regulation. In 2012, Virginia’s governor issued an executive order establishing a work group to develop a CCHD screening implementation plan, and legislation for mandatory screening was passed in 2014. In 2013, Massachusetts issued guidelines that recommended hospitals screen newborns and passed mandatory screening legislation in 2014. In 2014, Wisconsin enacted a law that allows the state department of health to add conditions to its state panel via regulation. Soon after enactment, regulations were issued adding CCHD to its panel.
FIGURE 2

Actions taken by states to adopt newborn screening for critical congenital heart defects — United States, 2011–2014*

* Actions taken as of December 2014.

Seven states and the District of Columbia support CCHD newborn screening as the standard of care with no mandate in place. Two states and the District of Columbia report that all hospitals are screening for CCHD (Table). By December 2014, among the 50 states and the District of Columbia, data collection within each newborn screening program varied from no data collection to collection of all screening results for every newborn. Of the states that have implemented, or are planning to implement CCHD screening, 24 reported current data collection, 14 reported planning future data collection, and 13 reported no plans for data collection (Table). The types of data collection vary from aggregate data collection only, collection of pass/fail results on all newborns, oxygen saturation results on all newborns, oxygen saturation results on failed newborns only, or a combination of these (Table).

Discussion

The increasing number of states mandating newborn screening for CCHD will likely increase the number of newborns screened, allowing for early identification and the potential for the prevention of morbidity and mortality. Most newborn screening conditions are tested through a heel stick test, with bloodspot analysis at public health or contracted laboratories. Screening for CCHD is a point-of-care test that occurs in hospitals before a newborn is discharged, with results entered into the medical record. Therefore, the role of public health is different than that for newborn bloodspot screening (7). This role might present challenges in data collection and surveillance for evaluating CCHD screening, because uniform reporting systems might not be established between public health programs, birthing centers, and hospitals (8). States have previously reported barriers to involvement with CCHD screening, such as the lack of legislative authority, staffing, funding, and informatics infrastructure (9). This report represents the first assessment of state legislative activities, requirements for collection of screening data, and progress made with screening activities, despite previously reported barriers. State-level data collection is vital for surveillance, monitoring of outcomes, and evaluation of state CCHD newborn screening programs. Although all types of screening data can be valuable, individual-level data are important for surveillance and evaluation. Collecting data related to factors associated with false-positive and false-negative results could help refine the recommended CCHD screening algorithm and screening activities (7). As states evaluate the implementation of CCHD screening, they are encouraged to consider programmatic changes that would improve their screening program, such as the inclusion of individual-level data reporting. Enactment of a state law or regulation does not translate into immediate and universal change in clinical practice. In addition to policy changes, the proper public health infrastructure, including infrastructure needs for data collection and reporting of CCHD screening results, is vital to ensure a successful CCHD newborn screening program. Summary What is already known on this topic? Congenital heart defects occur in approximately eight in every 1,000 live births, one fourth of which are considered to be critical congenital heart defects (CCHD). Newborn screening using pulse oximetry can detect hypoxemia, a clinical sign of CCHD. What is added by this report? This report represents the first assessment of state’s actions to adopt newborn screening for CCHD and requirements for collection of CCHD screening data. Forty-three states have taken action toward newborn screening for CCHD through statute, regulations, or hospital guidelines. Among the 43 states, 32 (74%) are collecting or planning to collect CCHD screening data. What are the implications for public health practice? State mandates for newborn screening for CCHD might increase the number of newborns screened, allowing for early identification and prevention of morbidity and mortality. Data collection and reporting are essential to evaluate the effect of this public health program.
  6 in total

1.  US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN).

Authors:  K A Pass; P A Lane; P M Fernhoff; C F Hinton; S R Panny; J S Parks; M Z Pelias; W J Rhead; S I Ross; D L Wethers; L J Elsas
Journal:  J Pediatr       Date:  2000-10       Impact factor: 4.406

Review 2.  U.S. newborn screening policy dilemmas for the twenty-first century.

Authors:  B L Therrell
Journal:  Mol Genet Metab       Date:  2001 Sep-Oct       Impact factor: 4.797

3.  Strategies for implementing screening for critical congenital heart disease.

Authors:  Alex R Kemper; William T Mahle; Gerard R Martin; W Carl Cooley; Praveen Kumar; W Robert Morrow; Kellie Kelm; Gail D Pearson; Jill Glidewell; Scott D Grosse; R Rodney Howell
Journal:  Pediatrics       Date:  2011-10-10       Impact factor: 7.124

4.  Newborn screening for critical congenital heart disease: potential roles of birth defects surveillance programs--United States, 2010-2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-10-26       Impact factor: 17.586

5.  Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the AHA and AAP.

Authors:  William T Mahle; Jane W Newburger; G Paul Matherne; Frank C Smith; Tracey R Hoke; Robert Koppel; Samuel S Gidding; Robert H Beekman; Scott D Grosse
Journal:  Pediatrics       Date:  2009-07-06       Impact factor: 7.124

6.  Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children.

Authors:  Ned Calonge; Nancy S Green; Piero Rinaldo; Michele Lloyd-Puryear; Denise Dougherty; Coleen Boyle; Michael Watson; Tracy Trotter; Sharon F Terry; R Rodney Howell
Journal:  Genet Med       Date:  2010-03       Impact factor: 8.822

  6 in total
  10 in total

1.  An Evaluation of the Addition of Critical Congenital Heart Defect Screening in Georgia Newborn Screening Procedures.

Authors:  Shelby T Rentmeester; Johanna Pringle; Carol R Hogue
Journal:  Matern Child Health J       Date:  2017-11

2.  Lessons Learned From Newborn Screening for Critical Congenital Heart Defects.

Authors:  Matthew E Oster; Susan W Aucott; Jill Glidewell; Jesse Hackell; Lazaros Kochilas; Gerard R Martin; Julia Phillippi; Nelangi M Pinto; Annamarie Saarinen; Marci Sontag; Alex R Kemper
Journal:  Pediatrics       Date:  2016-04-15       Impact factor: 7.124

3.  Critical Congenital Heart Disease Newborn Screening Implementation: Lessons Learned.

Authors:  Monica R McClain; John S Hokanson; Regina Grazel; Kim Van Naarden Braun; Lorraine F Garg; Michelle R Morris; Kathleen Moline; Keri Urquhart; Amy Nance; Harper Randall; Marci K Sontag
Journal:  Matern Child Health J       Date:  2017-06

4.  Pulse Oximetry Screening Has Not Changed Timing of Diagnosis or Mortality of Critical Congenital Heart Disease.

Authors:  Matthew J Campbell; William O Quarshie; Jennifer Faerber; David J Goldberg; Christopher E Mascio; Joshua J Blinder
Journal:  Pediatr Cardiol       Date:  2020-02-27       Impact factor: 1.655

5.  Are hypertensive disorders in pregnancy associated with congenital malformations in offspring? Evidence from the WHO Multicountry cross sectional survey on maternal and newborn health.

Authors:  S Bellizzi; M M Ali; E Abalos; A P Betran; J Kapila; C Pileggi-Castro; J P Vogel; M Merialdi
Journal:  BMC Pregnancy Childbirth       Date:  2016-07-29       Impact factor: 3.007

6.  CDC Grand Rounds: Newborn Screening for Hearing Loss and Critical Congenital Heart Disease.

Authors:  Scott D Grosse; Tiffany Riehle-Colarusso; Marcus Gaffney; Craig A Mason; Stuart K Shapira; Marci K Sontag; Kim Van Naarden Braun; John Iskander
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-08-25       Impact factor: 17.586

7.  Public Health Approach to Improve Outcomes for Congenital Heart Disease Across the Life Span.

Authors:  Kathy J Jenkins; Lorenzo D Botto; Adolfo Correa; Elyse Foster; Jennifer K Kupiec; Bradley S Marino; Matthew E Oster; Karen K Stout; Margaret A Honein
Journal:  J Am Heart Assoc       Date:  2019-04-16       Impact factor: 5.501

8.  Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018.

Authors:  Jill Glidewell; Scott D Grosse; Tiffany Riehle-Colarusso; Nelangi Pinto; Jeff Hudson; Rachel Daskalov; Amy Gaviglio; Erin Darby; Sikha Singh; Marci Sontag
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-02-08       Impact factor: 17.586

9.  Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths.

Authors:  Rahi Abouk; Scott D Grosse; Elizabeth C Ailes; Matthew E Oster
Journal:  JAMA       Date:  2017-12-05       Impact factor: 56.272

10.  Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review.

Authors:  Scott D Grosse; Cora Peterson; Rahi Abouk; Jill Glidewell; Matthew E Oster
Journal:  Int J Neonatal Screen       Date:  2017-12-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.